Ryo Fujioka

This paper investigates the metabolic stability and deposition of A{beta}3pE-42, a target of the Alzheimer's antibody donanemab, showing it is more stable than other A{beta}X-42 species and accumulates with age.

This study compares the roles of NEP and IDE in Aβ metabolism using double knockout mice, finding NEP primarily degrades insoluble Aβ and its deficiency contributes to AD pathology.

This study develops App knock-in mice without Swedish mutations to investigate β-secretase inhibition and endosomal abnormalities in Alzheimer's disease.

This paper introduces a new mouse model that accumulates wild-type human Aβ rapidly, showing more severe cored plaque pathology and neuroinflammation than existing models.